DK0412554T3 - Sustained-release-præparat til administration i hjernen - Google Patents

Sustained-release-præparat til administration i hjernen

Info

Publication number
DK0412554T3
DK0412554T3 DK90115389.0T DK90115389T DK0412554T3 DK 0412554 T3 DK0412554 T3 DK 0412554T3 DK 90115389 T DK90115389 T DK 90115389T DK 0412554 T3 DK0412554 T3 DK 0412554T3
Authority
DK
Denmark
Prior art keywords
sustained
brain
release preparation
administration
active substance
Prior art date
Application number
DK90115389.0T
Other languages
English (en)
Inventor
Toru Hayakawa
Toshiki Yoshimine
Keiji Fujioka
Yoshihiro Takada
Yoshio Sasaki
Tsunemasa Irie
Nobuyuki Fukushima
Original Assignee
Koken Kk
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Kk, Sumitomo Pharma filed Critical Koken Kk
Application granted granted Critical
Publication of DK0412554T3 publication Critical patent/DK0412554T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90115389.0T 1989-08-10 1990-08-10 Sustained-release-præparat til administration i hjernen DK0412554T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20848489 1989-08-10

Publications (1)

Publication Number Publication Date
DK0412554T3 true DK0412554T3 (da) 1994-12-12

Family

ID=16556927

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90115389.0T DK0412554T3 (da) 1989-08-10 1990-08-10 Sustained-release-præparat til administration i hjernen

Country Status (6)

Country Link
EP (1) EP0412554B1 (da)
JP (1) JP3187410B2 (da)
AT (1) ATE113470T1 (da)
DE (1) DE69013797T2 (da)
DK (1) DK0412554T3 (da)
ES (1) ES2066062T3 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077763C (en) * 1990-03-20 2007-07-31 Perry Bartlett Use of leukaemia inhibitory factor for regulating neuron development and maintenance
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
ES2185615T3 (es) * 1990-05-16 2003-05-01 Southern Res Inst Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
DE69232374T2 (de) * 1991-04-08 2002-08-29 Sumitomo Pharma Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
WO1992020400A1 (en) * 1991-05-24 1992-11-26 Sumitomo Pharmaceuticals Company, Limited Instrument for applying pharmaceutical to inside of brain
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
DE69327113D1 (de) * 1992-09-14 1999-12-30 Regeneron Pharma Methode zum erzeugen von analgie mittels neurotrophine
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
ES2293648T3 (es) * 1995-07-03 2008-03-16 Koken Co., Ltd. Preparaciones de genes que contienen atelocolageno.
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
AU708536B2 (en) * 1996-05-21 1999-08-05 Cytotherapeutics, Inc. System and method for delivery of cytokines using encapsulated cytokine-secreting cells
ES2349137T3 (es) * 2000-06-20 2010-12-28 Dainippon Sumitomo Pharma Co., Ltd. Preparación para transferir oligonucleótidos.
DK1407787T3 (da) 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
CN108840924A (zh) * 2018-06-20 2018-11-20 罗国球 一种高蛋白含量脑蛋白水解物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
DE3688188T2 (de) * 1985-12-27 1993-10-14 Koken Kk Verfahren zur Herstellung einer Formulierung mit verzögerter Freisetzung.
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
JPH03163032A (ja) 1991-07-15
ATE113470T1 (de) 1994-11-15
JP3187410B2 (ja) 2001-07-11
EP0412554B1 (en) 1994-11-02
EP0412554A2 (en) 1991-02-13
ES2066062T3 (es) 1995-03-01
DE69013797D1 (de) 1994-12-08
EP0412554A3 (en) 1991-09-25
DE69013797T2 (de) 1995-05-18

Similar Documents

Publication Publication Date Title
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
LU91894I2 (fr) 4-aminopyridine et ses dérivés
GB8804164D0 (en) Bandage for administering physiologically active compound
DE69327432T2 (de) Heilmittel für wunden und hämorrhoiden
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
NO884174D0 (no) Framgangsmaate for fremstilling av terapeutisk aktive tricykliske amidinoderivater.
TW197423B (da)
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO883485D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO880667L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
IT1178044B (it) Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
NO884176L (no) Fremgangsmaate for fremstilling av terapeutisk aktive amidinoderivater.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO875461D0 (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
NO882282D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazin-amider.
NO883959D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses